Warpspeed — Forecasts

Clinical trial forecasts powered by Monte Carlo simulation

Open (Prediction of future trial): 10 PREVAIL: Obicetrapib in Atherosclerotic Cardiovascular Disease Forecast 37% P(success) Hazard Ratio, 4P-MACE0.90[0.82 – 0.99] 0.700.800.901.001.101.20 Forecast: 37% probability of success on the primary 4-point MACE endpoint, with a simulated hazard ratio of 0.90 corresponding to roughly a 10% reduction in major cardiovascular events. Thesis: Three independent approaches to estimating obicetrapib's effect, grounded in its lipid-lowering profile and the CETP class track record from REVEAL, all converge on a modest ~10% event reduction, but PREVAIL…

saved by

• Katherine Driscoll

related reading

• Warpspeed — Missionwarpspeed.sh
• 🔮 IT’S OVER - The Oracle by Polymarketnews.polymarket.com
• Has pancreatic cancer met its match?worksinprogress.co
• 苏州生物医药产业园（BioBAY）biobay.com.cn
• Where are all the trillion dollar biotechs?ladanuzhna.xyz
• Weekly Dose of Optimism #208notboring.co
• The 23andMe Deal - Cremieux Recueilcremieux.xyz
• The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decadesstatnews.com
• near-term-xpt-accuracy.pdfstatic1.squarespace.com
• Neoadjuvant immune checkpoint blockade in high-risk resectable melanomanature.com
• Can Machine Learning Give Us Faster and Cheaper Clinical Trials?substack.com
• The Evidence Stack: We Benchmarked our ML Powered Research Synthesis Platform Against the Most Studied Drugs on Earthsingularitydynamics.substack.com